PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study.
Niels ReinmuthMaciej BrylIgor BondarenkoKostas SyrigosVladimir VladimirovManuela ZereuAngel H BairFiona HiltonKatherine LiauKazuo KasaharaPublished in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2020)
Pfizer.